Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

The development of a multiplex serological assay for avian influenza based on Luminex technology.

Germeraad E, Achterberg R, Venema S, Post J, de Leeuw O, Koch G, van der Wal FJ, Beerens N.

Methods. 2019 Apr 1;158:54-60. doi: 10.1016/j.ymeth.2019.01.012. Epub 2019 Jan 30.

PMID:
30707951
2.

A single-plasmid reverse genetics system for the rescue of non-segmented negative-strand RNA viruses from cloned full-length cDNA.

Peeters B, de Leeuw O.

J Virol Methods. 2017 Oct;248:187-190. doi: 10.1016/j.jviromet.2017.07.008. Epub 2017 Jul 22.

3.

Rapid emergence of a virulent PB2 E627K variant during adaptation of highly pathogenic avian influenza H7N7 virus to mice.

de Jong RM, Stockhofe-Zurwieden N, Verheij ES, de Boer-Luijtze EA, Ruiter SJ, de Leeuw OS, Cornelissen LA.

Virol J. 2013 Sep 5;10:276. doi: 10.1186/1743-422X-10-276.

4.

Effect of natural and chimeric haemagglutinin genes on influenza A virus replication in baby hamster kidney cells.

van Wielink R, Harmsen MM, Martens DE, de Leeuw OS, Peeters BP, Wijffels RH, Moormann RJ.

J Biotechnol. 2012 Dec 31;162(2-3):197-201. doi: 10.1016/j.jbiotec.2012.10.005. Epub 2012 Oct 16.

PMID:
23079079
5.

Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice.

Cornelissen LA, de Leeuw OS, Tacken MG, Klos HC, de Vries RP, de Boer-Luijtze EA, van Zoelen-Bos DJ, Rigter A, Rottier PJ, Moormann RJ, de Haan CA.

PLoS One. 2012;7(8):e44447. doi: 10.1371/journal.pone.0044447. Epub 2012 Aug 28.

6.

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W.

Vaccine. 2009 Apr 28;27(19):2588-93. doi: 10.1016/j.vaccine.2009.02.033. Epub 2009 Feb 20.

PMID:
19428865
7.

Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.

Janke M, Peeters B, Zhao H, de Leeuw O, Moorman R, Arnold A, Ziouta Y, Fournier P, Schirrmacher V.

Int J Oncol. 2008 Oct;33(4):823-32.

PMID:
18813797
8.

Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.

Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, Schirrmacher V.

Gene Ther. 2007 Dec;14(23):1639-49. Epub 2007 Oct 4.

PMID:
17914407
9.
10.

The P gene of Newcastle disease virus does not encode an accessory X protein.

Peeters B, Verbruggen P, Nelissen F, de Leeuw O.

J Gen Virol. 2004 Aug;85(Pt 8):2375-8.

PMID:
15269379
12.

Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.

Peeters BP, de Leeuw OS, Verstegen I, Koch G, Gielkens AL.

Vaccine. 2001 Feb 8;19(13-14):1616-27.

PMID:
11166884
13.

Genome replication of Newcastle disease virus: involvement of the rule-of-six.

Peeters BP, Gruijthuijsen YK, de Leeuw OS, Gielkens AL.

Arch Virol. 2000;145(9):1829-45.

PMID:
11043944
14.
18.

Molecular analysis of a flagellar core protein gene of Serpulina (Treponema) hyodysenteriae.

Koopman MB, Baats E, de Leeuw OS, van der Zeijst BA, Kusters JG.

J Gen Microbiol. 1993 Aug;139(8):1701-6.

PMID:
8409912
19.
20.

Synthesis of poly-3-hydroxyalkanoates is a common feature of fluorescent pseudomonads.

Huisman GW, de Leeuw O, Eggink G, Witholt B.

Appl Environ Microbiol. 1989 Aug;55(8):1949-54.

Supplemental Content

Loading ...
Support Center